Group 1 - Enghouse Systems Limited held its Annual General Meeting, which was accessible to all shareholders through a virtual platform [3] - Todd May, the VP and General Counsel, acted as the Chairman of the meeting [2] - Rob Medved, the Chief Financial Officer, served as the Secretary of the meeting [3] Group 2 - The first item of business was the appointment of scrutineers, with Rosa Garofalo from TSX Trust Company appointed for this purpose [4] - The meeting focused on formal business, with an operational update on the first quarter scheduled for a conference call the following day [3]

Core Viewpoint - President Trump is urging Federal Reserve Chair Jerome Powell to cut interest rates immediately, criticizing the Fed's typical approach of making rate changes only during scheduled meetings [1][7]. Group 1: Federal Reserve Actions - The Federal Open Market Committee is set to meet on March 17 to decide on changes to the key interest rate, which influences borrowing costs for consumers and businesses [2]. - The current target range for the Fed's benchmark rate is 3.50% to 3.75%, down from a previous range of 4.25% to 4.5% [8]. - Rate cuts have been made in the past during crises, such as the COVID-19 pandemic in 2020, but typically, changes are made at scheduled meetings [6][7]. Group 2: Economic Context - Rising energy prices, driven by the conflict involving Iran, are contributing to inflation pressures that the Fed is monitoring closely [3][6]. - Oil prices have surged past $100 a barrel, leading to increased gasoline and diesel prices, which complicates Trump's pledge to lower costs for Americans [6]. Group 3: Political Dynamics - Trump's public campaign for lower interest rates has intensified, with calls for rates to fall as low as 1% to stimulate economic growth [7]. - Tensions between the White House and the Federal Reserve are highlighted, with Fed officials asserting that rate decisions will be based on economic data rather than political pressure [11]. - A criminal investigation has been opened regarding Powell's prior testimony about cost overruns on the Fed's headquarters renovation, adding to the scrutiny of the Fed's operations [11][12].

Group 1: Lawsuit Overview - Costco is facing a proposed nationwide class action lawsuit seeking refunds for customers over higher prices charged due to tariffs ruled unconstitutional by the Supreme Court [1][2] - The lawsuit was filed in federal court in Illinois and aims to ensure that any refunds Costco receives for tariffs are returned to customers who faced higher prices [1][3] Group 2: Supreme Court Ruling - The Supreme Court ruled on February 20 that President Trump overstepped his authority in imposing tariffs under the International Emergency Economic Powers Act (IEEPA) [2] - This ruling allows companies, including Costco, to seek recovery of tariffs paid for imported goods [2][12] Group 3: Company Position and Future Plans - Costco has not committed to returning any portion of anticipated tariff refunds to consumers, only promising a possible future benefit to an indeterminate group of future shoppers [6] - CEO Ron Vachris indicated that if Costco receives tariff refunds, the company plans to use those funds to lower prices and improve value for shoppers [7] Group 4: Industry Context - Costco is among over 2,000 companies that have filed suits in the U.S. Court of International Trade to recover tariffs paid [3] - FedEx, another major player in the industry, is also facing a similar class action lawsuit regarding tariff refunds [8][9] Group 5: Economic Impact of Tariffs - A study by the Federal Reserve Bank of New York found that as of November 2025, U.S. businesses and consumers bore 86% of the tariff burden, while foreign exporters bore 14% [13] - The Congressional Budget Office noted that foreign exporters absorbed about 5% of the tariff costs, with the remaining 95% falling on U.S. firms and consumers [14]

Group 1 - The core viewpoint highlights CrowdStrike's strong momentum in artificial intelligence and its flexible subscription model, which are appealing to Wall Street analysts [1] Group 2 - Analysts are optimistic about CrowdStrike's growth potential due to its innovative AI capabilities [1] - The subscription model allows for scalability and adaptability, making it attractive for various customer segments [1] - The company's performance metrics indicate a positive trend, reinforcing investor confidence [1]

Core Viewpoint - The article discusses the role of James Foord as an economist and leader of The Pragmatic Investor, emphasizing the importance of building diversified portfolios to preserve and increase wealth in global markets [1]. Group 1: Company Overview - James Foord leads The Pragmatic Investor, which focuses on global macro, international equities, commodities, tech, and cryptocurrencies [1]. - The Pragmatic Investor aims to guide investors of all levels through various features, including a portfolio, weekly market updates, actionable trades, technical analysis, and a chat room [1]. Group 2: Market Focus - The investment group covers a wide range of asset classes, indicating a comprehensive approach to market analysis and investment strategies [1].

Core Insights - Tonix Pharmaceuticals achieved FDA approval and launched TONMYA, the first new medicine for fibromyalgia in over 15 years, with over 1,500 healthcare providers prescribing it to approximately 2,500 patients by February 27, 2026 [2][4] - The company reported a net product revenue of approximately $13.1 million for the full year 2025, an increase from $10.1 million in 2024, with TONMYA contributing approximately $1.4 million from its launch until year-end [17][19] - Tonix has a robust clinical pipeline, including TNX-4800 for Lyme disease prevention and TNX-102 SL for major depressive disorder, with plans for further development and FDA discussions in 2026 [2][6][9] Commercial Updates - TONMYA was launched on November 17, 2025, and has shown favorable early prescription trends, with cumulative prescriptions totaling approximately 4,200 by February 27, 2026 [4][3] - The company has deployed a salesforce of approximately 90 members to support the commercialization of TONMYA and enhance awareness among healthcare providers and patients [2][4] Financial Highlights - As of December 31, 2025, Tonix had approximately $207.6 million in cash and cash equivalents, a significant increase from $98.8 million in 2024 [13][30] - The company completed a $20.0 million registered direct offering with Point72 in December 2025 to fund commercialization and pipeline development [14] - Research and development expenses for 2025 were approximately $44.5 million, reflecting increased investment in pipeline projects [18] Product Pipeline - TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention, is set for FDA discussions regarding Phase 2/3 development in 2026 [6][9] - TNX-102 SL has received IND clearance for a Phase 2 study in major depressive disorder, with enrollment expected to begin in mid-2026 [9][12] - TNX-2900, targeting Prader-Willi syndrome, is planned for a Phase 2 trial initiation in Q1 2027 [11] Operational Highlights - The company has established partnerships for distribution and patient access programs to facilitate the commercialization of TONMYA [8] - Tonix is focusing on expanding payer engagement and establishing contracts with commercial payers while progressing discussions with Medicare and Medicaid [8]

Group 1 - BioSyent Inc. will report its financial results for Q4 and the full year ended December 31, 2025 on March 19, 2026 after market hours [1] - A presentation by René Goehrum, President and CEO, will be available on the company's website on the same date [1] - BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing, and distributing innovative pharmaceutical and oral health products [2] Group 2 - The company has 11,497,447 common shares outstanding as of the date of the press release [3] - For financial information and market quotes, the company directs to visit www.tmxmoney.com [3] - Contact information for further inquiries includes Mr. René C. Goehrum, President and CEO, with an email and phone number provided [4]

Core Viewpoint - Westport Fuel Systems Inc. will release its 2025 financial results on March 26, 2026, followed by a conference call and webcast on March 27, 2026 to discuss these results and other corporate developments [1]. Group 1: Financial Results Announcement - The financial results for 2025 will be announced after market close on March 26, 2026 [1]. - A conference call and webcast to discuss the financial results will take place on March 27, 2026 at 9:00 a.m. ET [1][2]. Group 2: Webcast Details - Participants can register for the conference call up to 60 minutes before the event [2]. - The webcast will be archived on Westport's website for future access [3]. Group 3: Company Overview - Westport is a technology and innovation company focused on providing alternative fuel and low-emissions transportation technologies [4]. - The company designs, manufactures, and supplies advanced components and systems to facilitate the transition from traditional fuels to cleaner energy solutions [4][5]. - Westport supports a variety of clean fuels, including natural gas, renewable natural gas, and hydrogen, helping OEMs and commercial transportation industries meet performance demands and regulatory requirements [5].

Group 1 - BioSyent Inc. will report its financial results for Q4 and the full year ended December 31, 2025 on March 19, 2026 after market hours [1] - A presentation by René Goehrum, President and CEO, will be available on the company's website on the same date [1] - BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing, and distributing innovative pharmaceutical and oral health products [2] Group 2 - The company has 11,497,447 common shares outstanding as of the date of the press release [3] - For financial information and market quotes, the company directs to visit www.tmxmoney.com [3] - Contact information for further inquiries includes Mr. René C. Goehrum, President and CEO, with an email and phone number provided [4]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting with competent advisors before making any financial decisions, particularly in relation to investments in cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and third-party materials intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as a recommendation or advice for investment actions [1]. - The accuracy and reliability of the information are not guaranteed, and users are cautioned against relying solely on the content provided [1]. Group 2 - The website discusses the complexities and high risks associated with cryptocurrencies and CFDs, highlighting the potential for significant financial loss [1]. - It encourages users to conduct their own research and fully understand the instruments and risks involved before making investment decisions [1].